Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$20.02
+0.7%
$17.64
$13.53
$35.25
$2.01B2.071.51 million shs1.36 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$18.22
+0.1%
$35.34
$16.88
$154.90
$1.79B0.452.19 million shs2.48 million shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$41.08
+1.6%
$43.34
$20.08
$57.28
$1.73B0.8686,567 shs274,097 shs
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
$16.78
+3.6%
$16.81
$11.56
$29.79
$421.76M2256,004 shs59,085 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.00%+19.17%+17.76%+31.11%-14.74%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.00%+6.46%-53.55%-66.53%-88.10%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.00%+1.81%-6.85%-12.63%+42.00%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
0.00%+1.42%-11.20%+30.75%+30.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.4834 of 5 stars
3.51.00.00.02.52.50.6
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4.7423 of 5 stars
4.22.00.04.22.41.71.9
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2.0591 of 5 stars
3.50.00.00.03.01.70.6
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
2.1135 of 5 stars
3.53.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.00
Buy$48.75143.51% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.44
Hold$60.88234.20% Upside
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
3.00
Buy$66.6762.28% Upside
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
3.00
Buy$49.33194.09% Upside

Current Analyst Ratings Breakdown

Latest TRML, TARS, BEAM, and SRPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Sell
6/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$123.00 ➝ $45.00
6/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
6/18/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$85.00 ➝ $40.00
6/18/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$24.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$50.00 ➝ $25.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$29.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$60.00 ➝ $30.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$100.00 ➝ $75.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$89.00 ➝ $29.00
6/2/2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$63.52M31.69N/AN/A$8.86 per share2.26
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.90B0.94$2.43 per share7.49$15.99 per share1.14
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$182.95M9.43N/AN/A$5.87 per share7.00
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/A$11.71 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$376.74M-$4.61N/AN/AN/A-609.24%-44.24%-30.97%8/5/2025 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$235.24M-$2.69N/A1.66N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$115.55M-$2.73N/AN/AN/A-44.91%-39.72%-25.74%8/6/2025 (Estimated)
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$73.21M-$3.21N/AN/AN/AN/A-26.75%-26.11%8/6/2025 (Estimated)

Latest TRML, TARS, BEAM, and SRPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million
5/6/2025Q1 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million
5/2/2025Q1 2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$0.91-$0.89+$0.02-$0.89N/AN/A
5/1/2025Q1 2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
N/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
8.81
8.81
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1.00
4.02
2.46
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.21
5.57
5.54
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/A
33.87
33.87

Institutional Ownership

CompanyInstitutional Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
90.01%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
91.89%

Insider Ownership

CompanyInsider Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.50%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7.70%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
8.97%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
13.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510100.56 million97.04 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,37298.28 million90.71 millionOptionable
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
5042.01 million38.25 millionOptionable
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
4425.68 million22.35 millionOptionable

Recent News About These Companies

Tourmaline Bio Inc News (TRML) - Investing.com
TRML - Tourmaline Bio Inc Dividends - Morningstar
TRML - Tourmaline Bio Inc Executives - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$20.02 +0.14 (+0.70%)
Closing price 07/3/2025 03:12 PM Eastern
Extended Trading
$20.19 +0.17 (+0.84%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$18.22 +0.03 (+0.14%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$18.22 0.00 (0.00%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Tarsus Pharmaceuticals stock logo

Tarsus Pharmaceuticals NASDAQ:TARS

$41.08 +0.63 (+1.56%)
As of 07/3/2025 02:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tourmaline Bio stock logo

Tourmaline Bio NASDAQ:TRML

$16.77 +0.59 (+3.61%)
Closing price 07/3/2025 03:43 PM Eastern
Extended Trading
$16.82 +0.04 (+0.24%)
As of 07/3/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.